Chinmay Jani, MD, of the University of Miami Sylvester Comprehensive Cancer Center, closes the discussion with Rajwanth R. Veluswamy, MD, MSCR, of the Perlmutter Cancer Center at NYU Langone Health, by naming the emerging data he is watching most closely in KRAS-mutated non-small cell lung cancer (NSCLC).
Rajwanth R. Veluswamy, MD, MSCR, and Chinmay Jani, MD, of the Perlmutter Cancer Center at NYU Langone Health and the University of Miami Sylvester Comprehensive Cancer Center, share their key takeaways on managing KRAS G12C-mutated non-small cell lung cancer.
Rajwanth R. Veluswamy, MD, MSCR, and Chinmay Jani, MD, of the Perlmutter Cancer Center at NYU Langone Health and the University of Miami Sylvester Comprehensive Cancer Center, discuss next-generation KRAS inhibitors in non-small cell lung cancer (NSCLC).
Rajwanth R. Veluswamy, MD, MSCR, and Chinmay Jani, MD, of the Perlmutter Cancer Center at NYU Langone Health and the University of Miami Sylvester Comprehensive Cancer Center, compare the tolerability of sotorasib and adagrasib in KRAS G12C-mutated non-small cell lung cancer.
Rajwanth R. Veluswamy, MD, MSCR, and Chinmay Jani, MD, of the Perlmutter Cancer Center at NYU Langone Health and the University of Miami Sylvester Comprehensive Cancer Center, discuss emerging KRAS G12C-directed agents in development for non-small cell lung cancer.
Rajwanth R. Veluswamy, MD, MSCR, and Chinmay Jani, MD, of the Perlmutter Cancer Center at NYU Langone Health and the University of Miami Sylvester Comprehensive Cancer Center, discuss second-line sequencing with sotorasib and adagrasib in KRAS G12C-mutated non-small cell lung cancer.
Rajwanth R. Veluswamy, MD, MSCR, of the Perlmutter Cancer Center at NYU Langone Health, and Chinmay Jani, MD, of the University of Miami Sylvester Comprehensive Cancer Center, review first-line immunotherapy outcomes in KRAS G12C-mutated non-small cell lung cancer.
Learn when to order tissue, liquid, and RNA testing to find KRAS G12C in lung adenocarcinoma and start treatment fast despite delayed results.
Learn when to order tissue, liquid, and RNA testing to find KRAS G12C in lung adenocarcinoma and start treatment fast despite delayed results.
Rajwanth R. Veluswamy, MD, MSCR, discusses universal KRAS testing, the frontline immunotherapy signal in KRAS G12C+ NSCLC, and next-generation G12C inhibitors.
